Functionalization and Modification of Naphthaquinone Analogs as HER2 Kinase Inhibitors by Lella, Divya Jyothi
Western Kentucky University
TopSCHOLAR®
Masters Theses & Specialist Projects Graduate School
5-2014
Functionalization and Modification of
Naphthaquinone Analogs as HER2 Kinase
Inhibitors
Divya Jyothi Lella
Western Kentucky University, divyajyothi.lella974@topper.wku.edu
Follow this and additional works at: http://digitalcommons.wku.edu/theses
Part of the Cells Commons, Chemical Actions and Uses Commons, Medicinal-Pharmaceutical
Chemistry Commons, and the Organic Chemistry Commons
This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Masters Theses & Specialist Projects by
an authorized administrator of TopSCHOLAR®. For more information, please contact connie.foster@wku.edu.
Recommended Citation
Lella, Divya Jyothi, "Functionalization and Modification of Naphthaquinone Analogs as HER2 Kinase Inhibitors" (2014). Masters
Theses & Specialist Projects. Paper 1325.
http://digitalcommons.wku.edu/theses/1325

FUNCTIONALIZATION AND MODIFICATION OF NAPHTHAQUINONE 
ANALOGS AS HER2 KINASE INHIBITORS 
A Thesis 
Presented to 
The Faculty of the Department of Chemistry 
Western Kentucky University 
Bowling Green, Kentucky 
In Partial Fulfilment 
Of the Requirements for the Degree 
Master of Science 
By 
Divya Jyothi Lella 
May 2014

iii 
 
ACKNOWLEDGMENTS 
First of all, I would like to express my sincere gratitude to my research advisors 
Dr. Cheryl Stevens and Dr. Bangbo Yan, for their patience, motivation, enthusiasm, and 
immense knowledge. Without their guidance and persistent help this thesis would not 
have been possible. If it was not for them, I would not have the knowledge that I have 
today. Their patience with me and helping me decipher my data, and also helping me 
with outside class work has given me the best experience in my graduate and research 
career.  I would like to express my hearty gratitude to my thesis committee member, Dr. 
Chad Snyder, who has spent his valuable time towards me and my defense. I would like 
to express my deepest gratitude to Dr. Hemali Rathnayake for helping me in learning 
many techniques and requirements to make compounds for this research with high purity. 
She also helped me in learning the fundamentals. I would like to thank Dr. Cathleen 
Webb, Head of the department and Safety officer Alicia McDaniel for providing financial 
means and laboratory facilities. I take this opportunity to express my sincere thanks to all 
faculty members of Department of Chemistry for guiding me throughout the period of 
study at the facility. 
My deepest thanks to my parents, L.Subba Rao and Lakshmi, and my fiancé 
Gangadhar V. for their endless love, encouragement, and support throughout my journey. 
Special thanks to all my friends who have willingly helped me a lot with their abilities 
and also for building enthusiasm and confidence in me.  
Last but not least, my heartful thanks to God for blessing me with good health and 
support throughout my life. 
iv 
 
CONTENTS 
 
Abstract.............................................................................................................................viii 
Chapter One: Introduction...................................................................................................1 
Chapter Two: Experimental...............................................................................................14 
Chapter Three: Results and Discussions............................................................................29 
Chapter Four: Conclusion..................................................................................................54 
Chapter Five: Future Work................................................................................................56 
References..........................................................................................................................57 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF FIGURES 
 
Figure 1. Cancer cells..........................................................................................................1 
Figure 2. Abnormal cell division.........................................................................................2 
Figure 3. Parts of breast.......................................................................................................3 
Figure 4. EGFR....................................................................................................................5 
Figure 5. Tyrosine kinase model..........................................................................................7 
Figure 6. Tyrosine kinase signaling.....................................................................................7 
Figure 7. Interaction of Emodin with amino acids............................................................10 
Figure 8. Interaction of Naphthaquinone compounds with amino acids...........................11 
Figure 9. Naphthaquinone parent compound.....................................................................13 
Figure 10. Structure of compound (1)................................................................................15 
Figure 11. Structure of compound (2)................................................................................16  
Figure 12. Structure of compound (3)................................................................................17 
Figure 13. Structure of compound (4)................................................................................19 
Figure 14. Structure of compound (5a) and (5b)...............................................................20 
Figure 15. Structure of compound (6)................................................................................22 
Figure 16. Structure of compound (7a) and (7b)...............................................................23 
Figure 17. Structure of compound (8)................................................................................25 
Figure 18. Structure of compound (9a) and (9b)...............................................................26 
Figure 19. 
1
H NMR of 1,5-dihydroxynaphthalene (1).......................................................30 
Figure 20. 
1
H NMR of 4,8-dibromo-1,5-dihydroxynaphthalene (2).................................32 
Figure 21. 
1
H NMR of 1,4,5,8-tetramethoxynaphthalene (3)............................................34 
Figure 22. 
1
H NMR of 2-Formyl-1,4,5,8-tetramethoxynaphthalene (4)............................37 
Figure 23. 
1
H NMR of 2-Formyl-1,4,5,8-tetramethoxynaphthalene (4) with methoxy 
protons……………………………………………………………………………………38 
Figure 24.
 1
H NMR of 2-Formyl-5,8-dimethoxy-1,4-naphthaquinone (5a)……………..42 
vi 
 
Figure 25. 
1
H NMR of 2-Formyl-1,4-dimethoxy-5,8-naphthaquinone (5b).....................43 
Figure 26. 
1
H NMR of 2-(1-Hydroxyethyl) -1,4,5,8-tetramethoxynaphthalene (6) from 
1.5 ppm - 2.4 ppm..............................................................................................................45 
Figure 27. 
1
H NMR of 2-(1-Hydroxyethyl) -1,4,5,8-tetramethoxynaphthalene (6) from 
5.1 ppm - 7.5 ppm.
 ………………………………………………………………………46 
Figure 28.
 1
H NMR of 2-(1-Hydroxyethyl)-5,8-dimethoxy-1,4-naphthaquinone (7a)......47 
Figure 29.
1
H NMR of 2-(1-Hydroxyethyl)-1,4-dimethoxy-5,8-naphthaquinone (7b)......48 
Figure 30. 
1
H NMR of 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene (8).............50 
Figure 31. 
1
H NMR of 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene (8).............51 
Figure 32.
 1
H NMR of 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene (8).............51 
Figure 33. 
1
H NMR of 2-Hydroxymethyl-5,8-dimethoxy-1,4-naphthaquinone (9a)........52 
Figure 34. 
1
H NMR of 2-Hydroxymethyl-1,4-dimethoxy-5,8-naphthaquinone (9b)........53 
Figure 35. Schematic of two fractions...............................................................................54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES 
 
Table 1. List of R groups...................................................................................................13 
Table 2. List of naphthaquinone analogues……………………………………………...55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
LIST OF SCHEMES 
Scheme 1: Representation of general synthesis.................................................................13 
Scheme 2: Preparation of compound (1) from starting material........................................15 
Scheme 3: Preparation of compound (2) from compound (1)...........................................16 
Scheme 4: Preparation of compound (3) from compound (2)...........................................18 
Scheme 5: Preparation of compound (4) from compound (3)...........................................19 
Scheme 6: Preparation of compound (5a) and (5b) from compound (4)..........................21 
Scheme 7: Preparation of compound (6) from compound (4)...........................................22 
Scheme 8: Preparation of compound (7a) and (7b) from compound (6)..........................24 
Scheme 9: Preparation of compound (8) from compound (4)...........................................25 
Scheme 10: Preparation of compound (9a) and (9b) from compound (8)........................27 
Scheme 11: Mechanism of N-bromosuccimide.................................................................31 
Scheme 12: Mechanism of Vilsmeier Haack reaction.......................................................36 
Scheme 13: Mechanism of cerium ammonium nitrate on R groups..................................40 
Scheme 14: Mechanism of cerium ammonium nitrate on R groups..................................41 
ix 
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Directed by: Cheryl Stevens, Bangbo Yan, and Chad Snyder 
Department of Chemistry Western Kentucky University 
HER2 overexpression in breast cancer tumors predicts lower overall survival.  
Because of the aggressive nature of HER2 tumors and the association with metastatic 
disease, the HER2 receptor holds great promise as a therapeutic target in metastatic breast 
cancer.  We are developing small molecule inhibitors that bind to the ATP binding site of 
the tyrosine kinase domain in order to inhibit tyrosine auto-phosphorylation. This process 
controls biological pathways that mediate the cell growth. In normal cells this process is 
highly controlled.  
We are targeting the modification of the side chain of the hydroxy methyl group 
of 2-Hydroxy methyl-5,8-dimethoxy-1,4-naphthaquinone. These compounds should 
inhibit the tyrosine kinase cascade of reactions thereby suppressing the overexpression of 
HER2 shutting down the tumor growth. The synthesis and characterization of a series of 
substituted naphthaquinone analogs with different increasing chain lengths will be 
reported.
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CHAPTER ONE 
INTRODUCTION 
1. Cancer 
Cancer is a group of disease that involves disregulated cell growth and cells are 
the building structures of our body. Usually our body has a very unique feature of 
producing new cells as we require them and also replaces the old cells according to the 
requirements of the body.
1
 This regular process may go wrong. The DNA of a cell can 
become affected for the process of normal cell division and growth (Figure 1). When this 
process takes place, cells do not get eliminated and leads to the formation of new cells 
when the body do not require and it leads to uncontrolled cell signalling and cell growth 
(Figure 2). This uncontrolled growth leads to the formation of massive cells called a 
tumor.
2
 
 
 
Figure 1: Schematic of cancer cells
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Different types of Cancer include: 
 Leukemia – a type of cancer that starts in tissue of blood such as the bone marrow, 
produces a large number of abnormal blood cells and enters the blood and starts 
multiplication of the cells.
4
 
 Sarcoma – a type of cancer that begins mainly in cartilage, bone, fat, or other connective 
or supportive tissue. 
 Central nervous system cancers – cancer which mainly affects spinal cord and brain. 
 Carcinoma – Tissues covering the internal organs are mainly affected in this type of 
cancer. There are many subtypes of carcinoma, including adenocarcinoma, 
and transitional cell carcinoma.
5
 
 Lymphoma and myeloma – cancer that begins in the immune system. 
 
Figure 2: Schematic of abnormal cell division
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2.  Breast Cancer 
Breast cancer is an epidemic disease mainly responsible for women’s death in the 
United States. In 2013, the number of new cases of breast cancer were reported to be 
about 232,340 and the number of deaths of breast cancer were reported to be 39,620. The 
most widely occurred type of breast cancer is Ductal carcinoma and begins in cells that 
line a breast duct (Figure 3). In addition to this, about 70 % of women suffering with 
breast cancer have ductal carcinoma.
6
 The second most widely seen type of breast cancer 
is Lobular carcinoma that begins in a lobule of the breast. About 10% of women with 
breast cancer have lobular carcinoma and it is less occurred compared to ductal 
carcinoma. Few other women have a mixture of ductal and lobular type or they have a 
less common type of breast cancer.
 
 
Figure 3. Schematic of parts of breast
6 
3. Tyrosine Kinase Inhibitors 
Tyrosine kinases are an important subgroup of protein kinases, which are 
enzymes that catalyse the transfer of phosphate to target proteins. They are the primary 
4 
 
mediators of the signalling network that transmits extracellular signals into the cell.
7
 The 
phosphorylation of proteins is an important step of cellular signal transduction regulating 
cell differentiation, cell growth, cell migration and influencing apoptotic mechanisms. 
Gene amplification, overexpression, functional alterations caused by mutations and 
abnormal autocrine-paracrine growth factor loops contribute to constitutive signalling 
ultimately resulting in the manifestation of disregulated cell growth and cancer. The 
specificity of protein kinases for determined substrate proteins depends on the amino acid 
sequence of their binding site.
8
  
Tyrosine kinase inhibitors may be effective in the treatment of HER2- positive 
metastatic breast cancers as they can inhibit truncated HER2, HER2∆16 and the full 
length HER2. Treatment with Lapatinib, a multi-tyrosine kinase inhibitor was shown to 
extend the time to progression by four months in a phase III study of women with HER2-
positive metastatic breast cancer.
9 
3.1 Epidermal Growth Factor Receptor 
 The epidermal growth factor receptor (EGFR) is part of a family of plasma 
membrane receptor tyrosine kinases that control many important cellular functions, such 
as cell growth, cell proliferation and apoptosis. Dysregulation of the EGFR signal 
transduction pathway has been implicated in tumorigenesis and cancer progression, 
making it a clinically relevant target for breast cancer treatments. The EGFR is a 
ubiquitous 170-kDa membrane spanning glycoprotein composed of an amino-terminal 
extracellular ligand-binding domain that contains the tyrosine kinase domain and a 
carboxy-terminal region that contains critical tyrosine residues and receptor regulatory 
5 
 
motifs (Figure 4). After ligand binding, EGFR dimerization occurs resulting in high 
affinity ligand binding activation of a cascade of biochemical and physiologic responses 
that are involved in the mitogenic signal transduction of cancer cells.
10 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic of EGFR
11 
3.2 Human Epidermal Growth Factor Receptor 2 
 HER2 (Human Epidermal Growth Factor Receptor 2) also known 
as Neu, ErbB2, is a protein in humans that is encoded by the ERBB2 gene.
12
 The HER2 
gene is amplified and as a result over-expressed in 30% of breast cancer occurrences and 
is associated with poor prognosis, increased resistance to chemotherapy, and enhanced 
metastatic potential.  
 
 
 
 
 
extracellular 
 
 
intracellular 
ATP binding site 
ligand binding domain 
tyrosine 
kinase 
domain 
C-terminus 
hydrophobic 
transmembrane 
domain 
6 
 
3.3 Tyrosine Kinase Signalling 
Ligand binding induces formation of homo and heterodimers of growth factor 
receptors. Tyrosine kinase activity is activated leading to auto-phosphorylation in several 
tyrosine residues.
13
A cascade of reactions begins involving cell function and signalling 
pathways that regulate cell growth, cell death, angiogenesis, and cell differentiation. In 
normal cells, growth is a highly controlled process where as in tumor cells the process is 
highly uncontrollable and unlimited which leads to uncontrolled TK signalling resulting 
in gene amplification and disregulated cell growth (Figure 6). The HER2 activation has 
been implicated in processes involved in tumor growth and progression including cell 
proliferation, inhibition of apoptosis, angiogenesis, and metastasis.
14 
Several agents have been developed for the treatment of HER2-over-expressing 
breast cancers that target the HER2 receptor.
15
 These include monoclonal antibodies and 
small molecule tyrosine kinase inhibitors, with the most well-known being Transtuzumab 
(Herceptin) and Lapatinib (Tykerb) shown bound in the TK active site (Figure 5). 
 
 
Figure 5: Binding pocket of tyrosine kinase receptor
16 
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Figure 6: Schematic of tyrosine kinase signaling pathway
17
 
4. Naphthaquinone Compounds 
4.1 Background 
 Naphthaquinones are the organic compounds present in many drugs used in the 
treatment of solid tumors. Commonly used naphthaquinones include Daunorubicin and 
Anthracyclines. The principle mechanism of naphthaquinones involve the inhibition of 
DNA topoisomerase-II in the cells.
18
 The naphthaquinones when combined with 
semiquinone result in a reactive super oxide radical. Semiquinone along with super oxide 
radical causes breakage of DNA strand by the generation of hydroxyl radical. 1,4-
naphthaquinones is an important example of quinone family and is industrially used as a 
raw material for agro chemicals, pharmaceuticals and other functional chemicals.
19,20
 1,4-
naphthaquinones occur widely among microorganisms and fungi and these have been 
studied regarding their colors and structures by many researchers. These days, 
Ligand 
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researchers are placing their hopes on such physiological activities as antitumor and 
antibiotic actions. There are also many patents for naphthaquinones as drugs for 
thrombosis, delayed hypersensitivity and the healing of wounds. 1,4-naphthaquinone 
derivatives are used very effectively as anti fungals and anti bacterials.
21
 They are also 
very much promising as anti-cancer agents. Vitamin K compounds play an important role 
in bone and vascular health. They undergo both redox cycling and acylation reactions, 
which is very usual to quinones for biological applicability. The cell death of cancer 
created by Menadione is in relation with protein kinase pathway activated by mitogen. 
The versatile naphthaquinone structure provides a very unique spatial configuration that 
allows various substitution reactions. The diversity in substitution led to synthesis of 1,4-
naphthaquinone derivatives in addition to semisynthetic naphthaquinones isolated from 
natural sources. 
4.2 Naturally occurring compounds 
Emodin, a natural purgative resin anthraquinone from Rheum emodi was the only 
drug that inhibited the therapeutically resistant oncogenic HER2 receptor (Figure 7). 
Based on the orientation of emodin in the binding pocket of the protein, residues that 
could be targeted for developing a good inhibitor were identified. HER2 is encoded by 
the ERBB2 gene protein in humans which communicates molecular signals from outside 
the cell to inside the cell. In most of the breast cancer types pathogenesis is mainly due to 
amplification of cells. In cancer cells, the HER2 protein can be expressed up to 100 times 
more than in normal cells leading to strong and constant proliferative signalling that helps 
to shut down the tumor formation.
22 
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Figure 7. Interaction of Emodin with amino acids
23
 
Since compounds are naphthaquinone analogs and are structurally similar to 
emodin, we are assuming that naphthaquinone compounds may also interact with the 
amino acids. For example, the oxygen atom of the O-H group of one side of the 
naphthaquinone parent ring interacts with the threonine 95 amino acid and the O-H 
hydrogen atom interacts with the glutamine 96 amino acid. The oxygen atom of the O-H 
bond of the R group of the side chain interacts with the lysine 50 amino acid and its 
hydrogen atom interacts with the aspartate 160 amino acid (Figure 8).  
10 
 
 
  
Figure 8. Interaction of naphthaquinone compounds with amino acids
24 
4.3 Biological activity of 1,4-Naphthaquinones 
Among the diverse biological activities of naphthaquinone derivatives, the most 
widely studied is the anti-cancer activities. The molecular mechanisms associated with 
their anticancer activity have been explored only in few patents.
25
 The biological activity 
of 1,4-naphthaquinone is mainly due to the existence of carbonyl groups on the structure 
that have the capability to accept one and two electrons to facilitate the formation of the 
corresponding radical anion species and acid base properties. Recently it has been studied 
that the tautomerism in 1,4-naphthaquinones due to the  presence of alcohol groups at 5
th
  
and 8
th
  positions, reduces the electrophilic nature of the parent drug which in turn is 
responsible for the biological activity of naphthazarin.
26
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5. Synthesis of New Tyrosine Kinase Inhibitors / Naphthaquinones 
We have proposed to introduce R groups with the increasing chain length 
hydrogen (H), methyl (CH3), ethyl (C2H5), propyl, hydroxyethyl in the side chain of the 
naphthaquinone parent compound. The main goal of this research is to synthesize the 
compounds for the future study of HER2 inhibition activities with the different R groups 
with increasing chain lengths and also observe at which chain length of the R group best 
potency and metabolic HER2 inhibition activity will be achieved (Figure 9). The 
activities of the compounds will be screened by selecting each compound and docking 
studies will be performed to analyse which compound best fits into the protein pocket and 
interacts well with the HER2 receptor. New quinone inhibitors will be identified that 
dramatically inhibit the growth of HER2 and HER2∆16 overexpressing breast cancer 
MCF-7 cell lines.
27 
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Figure 9: Schematic of naphthaquinone parent compound 
Table 1: R groups 
 
 
 
 
 
 
 
 
 
 
 
R groups 
H 
CH2OH 
CH(OH)CH3 
CH(OH)(CH2)3CH3 
CHO 
1 
 
2 
3 
7 
4 
8 
6 
5 
13 
 
 
 
Scheme 1: Representation of general synthesis
28 
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CHAPTER TWO 
EXPERIMENTAL 
 
2.1 Materials  
All reactions were carried out using standard Schlenk techniques under an argon   
atmosphere unless otherwise noted. The chemicals used in the preparation of compounds 
include 1,5-dihydroxynaphthalene, copper(I) iodide, N,N-dimethyl formamide, 
tetrabutylammoniumbromide, sodium hydroxide, acetonitrile were purchased from Alfa 
Aesar and also used as received. Chloroform-D, sodium dithionite, N-bromosuccimide, 
phosphoryl chloride, dimethyl sulfate, methyl magnesium iodide, lithium aluminium 
hydride, tetrahydrofuran were purchased from Sigma-Aldrich. 
2.2 Characterization 
1
H NMR spectra were recorded on a JEOL-500 MHz NMR spectrometer and 
were referenced to residual solvent peaks. Infrared spectra were recorded on Perkin 
Elmer Spectrum One Fourier Transform Infrared Spectrometer. Elemental analysis was 
performed with CHN Tru Spec. Melting points were taken on a standard Mel-Temp 
apparatus. 
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2.3 Synthesis  
2.3.1. 1,5-dimethoxynaphthalene(C12H12O2)(1) 
Structure  
 
Figure 10: Structure of compound (1) 
Reaction 
 
Scheme 2: Preparation of compound (1) from 1,5-dihydroxynaphthalene (Starting 
material) 
28
   
Sodium dithionite (1 g, 5 mmol), tetrabutylammonium bromide (1.6 g, 5 mmol),  
sodium hydroxide (7.2 g, 180 mmol)  were added to the solution of 1,5-
dihydroxynaphthalene (12 g, 75 mmol) in THF-H2O (150ml)(2:1) in portions under 
argon. A deep brown color was formed leading to slow formation of yellow color on the 
walls of the round bottom flask. Then dimethyl sulfate (14.3 mL, 150 mmol) was added 
drop wise to the solution while keeping the temperature below 30C. The resulting 
(1) 
 
(CH3)2SO4 
16 
 
mixture was stirred at room temperature. After 4 h, there was a separation of two layers 
aqueous phase and organic phase (Scheme 2). The solid was collected by filtration under 
suction and washed several times with deionised water for about 30 min to remove the 
sodium hydroxide to leave yellow solid (Figure 10)(13.8 g, 98%).
29
 Melting point: 183- 
185 C. 1H NMR (500 MHz, CDCl3, ppm):  6.85 (d, 2H, 
3
J= 6.2 Hz, ArH), 3.89 (s, 6H, 
OCH3), 7.36 (t, 2H, 
3
J=5.4 Hz, ArH), 7.83 (d, 2H, 
3
J=8.5 Hz). IR (UATR cm
-1
) 
1591(C=C), 2961, 2936 (Csp3-H), 3008, 3074 (Csp2- H). Elemental analysis calculated for 
C12H12O2: C, 76.50; H, 6.30%.  Found C, 76.60; H, 6.42%. 
2.3.2. 4,8-dibromo-1,5-dimethoxynaphthalene(C12H10O2Br2) (2) 
Structure 
 
 
Figure 11: Structure of compound (2) 
Reaction 
 
Scheme 3: Preparation of compound (2) from compound (1)
28
 
(2) 
 
(1) 
 
(2) 
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A solution of N-bromosuccimide (4.16 g, 125 mmol) in acetonitrile (34.8 mL) 
was added drop wise to a suspension of compound (1) 1,5-dimethoxynaphthalene (2 g, 50 
mmol) in acetonitrile (31.8 mL), which was cooled in a salt ice bath maintaining the  
temperature at -5°C. After 3 h of stirring at room temperature under argon the product 
precipitated out (Scheme 3). 
30
 The resulting solid was collected by filtration under 
suction, washed with acetonitrile (4 × 25 mL) and then methanol to afford  cream white  
powder (Figure 11) (1.60 g, 92%). Melting point: 185-187°C. 
1
H NMR (500 MHz, 
CDCl3, ppm) 3.75 (s, 12H, OCH3),  6.86 (d, 2H, 
3
J=5.5 Hz, ArH),  7.98 (d, 2H, 3J=1 
Hz, ArH). IR (UATR, cm
-1
): 1591(C=C), 2936, 2964 (C sp3-H), 3008 (C sp2– H). 
Elemental Analysis for C12H10O2Br2: Calculated, C, 41.65; H, 2.91%. Found, C, 41.70; 
H, 3.01%. 
2.3.3. 1,4,5,8-tetramethoxynaphthalene (C14H16O4) (3) 
Structure 
 
 
Figure 12: Structure of compound (3) 
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Reaction 
 
 
Scheme 4: Preparation of compound (3) from compound (2) 
28 
A mixture of 1,5-dibromo-4,8-dimethoxynaphthalene (1.52 g, 32 mmol), sodium 
methoxide (0.83 g, 106 mmol), copper (I) iodide (2.91 g, 106 mmol), N,N-
dimethylformamide (52.91 mL) and methanol (52.94 mL) was refluxed for 30 h. The 
cooled mixture was poured into ice water and the resulting precipitate was filtered, 
washed with water and dried overnight (Scheme 4). Then it was extracted with 40 mL 
chloroform (solid-liquid extraction) for every 1 g and brought to boil in oil bath, it was 
later filtered and dried over anhydrous magnesium sulfate (Figure 12).
31
 The resulting 
mixture was concentrated and the residue was chromatographed on silica gel with 
dichloromethane and ethyl acetate 1:1 as eluent and the fractions taken from the column 
were recrystallized from ligroin to afford 0.75 g white crystals (0.75 g, 70.25%). Melting 
point: 166-167°C. 
1
H NMR (500MHz, CDCl3, ppm)  6.84 (s, 4H, ArH), 3.88 (s, 12H, 
OCH3) IR (UATR, cm
-1
): 1605 (C=C), 2995, 2940 (C sp3-H), 3008 (C sp2– H).  Elemental 
Analysis for C14H16O4: Calculated, C, 67.73; H, 6.50. Found, C, 67.80; H, 6.58%. 
 
 
 
 
(2) 
 
(3) 
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2.3.4. 2-Formyl-1,4,5,8-tetramethoxynaphthalene (C14H16O4) (4) 
Structure  
 
 
Figure 13: Structure of compound (4) 
Reaction 
 
 
Scheme 5: Preparation of compound (4) from compound (3)
28
   
A solution of 1,4,5,8-tetramethoxynaphthalene (3) (1.5 g, 24.3 mmol) in 
chloroform (12.5 mL) was added to a mixture of phosphoryl chloride (4.8 mL, 120.8 
mmol) and N,N-dimethylformamide (2.5 mL, 120.8 mmol) and the mixture was refluxed 
for 6 h. It was then decomposed with ice water and allowed to stir for 30 min and then 
extracted with chloroform. The chloroform solution was washed with brine and dried 
over anhydrous magnesium sulfate (Scheme 5). Evaporation of the solvent gave a residue 
which was crystallised from hexane to obtain yellow crystals.
32
As the resulting solid was 
(3) 
 
(4) 
 
20 
 
sticky due to small amounts of DMF, the residue was chromatographed on silica gel with 
dichloromethane and ethylacetate 1:1 as eluent and the fractions were evaporated 
resulting in removal of DMF and pure solid of (Figure 13) (4) (1 g, 66.6%). Melting 
point: 124-125°C. 
1
H NMR (500 MHz, CDCl3, ppm):  10.56 (s, 1H), 7.16 (s, 1H), 
7.01(d, 1H, 
3
J=5.5 Hz), 6.93(d, 1H, 
3
J=9.5 Hz), 3.99 (s, 3H, OCH3), 3.98(s, 3H, OCH3), 
3.91(s, 3H, OCH3). IR (UATR cm
-1)
:1673 (C=O), 2845, and 1067cm
-1
 (OCH3). 
Elemental Analysis for C14H16O4: Calculated, C, 65.21; H, 5.84. Found, C, 65.44; H, 
5.94%. 
2.3.5. 2-Formyl-1,4,5,8-tetramethoxynaphthaquinone (C13H10O5) (5) 
Structure  
                                        
 
Figure 14: Structure of compounds (5a) and (5b) 
R= CHO 
 
 
 
 
 
(5b) 
 
(5a) 
 
+ 
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Reaction 
 
 
Scheme 6: Preparation of compounds (5a) and (5b) from compound (4)
31
  
A solution of cerium ammonium nitrate (CAN) (2.5-3mmol) (1.37-1.40 g) in 
water (5 mL) was added drop wise to a solution of compound (5) (0.292 g, 1 mmol) in 
acetonitrile (10 mL) at room temperature for 30 min. When the addition of CAN started, 
the solution turned from a light brown color to an orange color and then finally to a deep 
orange color (Scheme 6). The reaction mixture was diluted with water, extracted with 
chloroform, washed with brine, dried over sodium sulfate, and concentrated.
31
 The 
residue was purified by chromatography on silica gel with dichloromethane and ethyl 
acetate 1:1 as eluent and recrystallized (Figure 14). 
Fraction a: 2-Formyl-5,8-dimethoxy-1,4-naphthaquinone  
Reddish-orange crystals from ligrone and benzene. Melting point: 160-161 °C. 
1
H 
NMR (500 MHz, CDCl3, ppm):  = 3.99, 4.01 (s, 6H, OCH3), 6.85 (s, 2H, quinone ring), 
7.75 (s, 2H, benzene ring), 10.49 (s, H). IR (UATR cm
-1)
: 1650 (C=O), 1582, 1565, 1045, 
1020 cm
-1
.  
 
 
 
(5a) 
 
(5b) 
 
(4) 
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Fraction b: 2-Formyl-1,4-dimethoxy-5,8-naphthaquinone 
The first fraction from silica gel chromatography. Melting point: 159-160° C. 
1
H 
NMR (500 MHz, CDCl3, ppm):  = 3.96 (s, 6H, OCH3), 6.77 (s, 2H, quinone ring) and 
7.32 (s, 2H, benzene ring). IR (UATR cm
-1)
: 1650 (C=O), 1582, 1565, 1045, 1020 cm
-1
.  
2.3.6. 2-(1-Hydroxyethyl)-1,4,5,8-tetramethoxynaphthalene (C16H20O5) (6)
 
Structure  
 
 
R= CH(OH)CH3 
Figure 15: Structure of compound (6) 
Reaction 
 
 
Scheme 7: Preparation of compound (6) from (4) 
(6) 
 
(6) 
 
(4) 
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  2-Formyl-1,4,5,8-tetramethoxy naphthalene (4) (0.1 g, 10 mmol) was added to 
anhydrous THF (1.45 mL) was allowed to stir under argon for 10 min and then the flask 
was placed in ice bath maintaining the temperature 0° C. Next methyl magnesium iodide 
0.35 mL (8 drops, 30 mmol) was added drop wise for about 30 min and the mixture was 
stirred at room temperature for 1 h, monitored by TLC and then decomposed with 2.1 mL 
of 2M NH4Cl solution in 5 mL of deionised water. Then it was allowed to stir for 15 min 
and extracted with chloroform (100 mL × 3)( Scheme 7).
32
 The usual work up and 
purification of the crude product by silica gel chromatography with dichloromethane and 
ethyl acetate 1:1 as eluent and recrystallization from hexane gave the sample of (Figure 
15) (5) (700 mg, 70%).
28
 Melting point: 84- 85°C. 
1
H NMR (500MHz, CDCl3 ,  ppm):  = 
1.50 (d, 3H, 
3
J=4.5 Hz, CH3), 2.23 (broad singlet, 1H, OH), 3.76, 3.89 (each s, 3H, 
OCH3), 3.93 (s, 6H, OCH3), 5.43 (q, 1H, CH), 6.81 (s, 2H, ArH) and 7.00 (s, 1H, ArH). 
IR (UATR cm
-1
): 3450 (OH), 1600 and 1070 cm
-1
. Elemental Analysis for C16H20O5: 
Calculated, C, 65.73; H, 6.91. Found, C, 65.62; H, 7.00%. 
2.3.7. 2-(1-Hydroxyethyl)-1,4,5,8-tetramethoxynapthaquinone(C14H14O5)(7) 
Structure  
                                        
Figure 16: Structure of compounds (7a) and (7b) 
R = CH(OH)CH3 
(7b) 
 
(7a) 
 
+ 
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Reaction 
 
       (6)                                                                        (7a)                                   (7b) 
Scheme 8: Preparation of compounds (7a) and (7b) from (6) 
A solution of cerium ammonium nitrate (CAN) (2.5 - 3mmol) (1.37 - 1.40 g) in 
water (5 mL) was added drop wise to a solution of compound (6) (0.292 g) in acetonitrile 
(10 mL) at room temperature for 30 min. When the addition of CAN started, the solution 
turned from a light brown color to an orange color and then finally a deep orange color 
(Scheme 8). The reaction mixture was diluted with water, later extracted with 
chloroform, washed with brine, finally dried over sodium sulfate, and concentrated 
(Figure 16). The residue was purified by chromatography on silica gel with 
dichloromethane: ethyl acetate 1:1 as eluent and recrystallized.
31, 32
  
Fraction a: 2-(1-Hydroxyethyl)-5,8-dimethoxy-1,4-naphthaquinone  
The second fraction  from silica gel chromatography with dichloromethane and 
ethyl acetate as eluent ; orange crystals (from ligroin - benzene); Melting point: 144-
145°C; 
1
H NMR (500 MHz, CDCl3,  ppm):  1.48 (3H, CH3), 2.70 (d, 1H,
3
J =2.50 Hz, 
OH), 3.96, 3.97, (s, 3H, OCH3), 4.94(m, 1H, 
3
J= 4.50 Hz, CH), 6.78(d, 1H, 
3
J =3.0 Hz 
quinone ring) and 7.32 (s, 2H, benzene ring). IR (UATR cm
-1
): 3480 (OH), 1650 (C=O), 
1050 and 1020 cm
-1
.  
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Fraction b: 2-(1-Hydroxyethyl)-1,4-dimethoxy-5,8-naphthaquinone 
The first fraction from silica gel chromatography; an orange semisolid; 
1
H NMR 
(500 MHz, CDCl3, ppm):  1.56 (d, 3H,
3
J=3.2 Hz CH3), 2.2 (broad singlet, 1H, OH), 
3.83, 3.99 (s, 3H, OCH3), 5.30 (q, 1H, 
3
J=4.0 Hz, CH), 6.76 (s, 2H, quinone ring H) and 
7.55 (s, 1H, quinone ring H). 
2.8. 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene(C15H18O5)(8) 
Structure  
 
 
Figure 17: Structure of compound (8) 
R = CH2OH 
Reaction 
 
Scheme 9: Preparation of compound (8) from (4) 
(8) 
 
(4) 
 
(8) 
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A sample of 2-Formyl-1,4,5,8-tetramethoxy naphthalene  (4) (1.01 g) in 
anhydrous THF (1.73 mL) was placed in the ice bath and then the solution of lithium 
aluminium hydride in anhydrous THF was added drop wise for about 20 min and then the 
reaction mixture was allowed to stir for 4 h. Now the reaction mixture was decomposed 
with 1 M HCl and allowed to stir for 30 min. Once the addition of HCl started a white 
precipitate of lithium chloride was formed (Scheme 9). The reaction mixture is extracted 
with chloroform (50 mL ×3) and the chloroform layer was washed with brine, dried over 
sodium sulfate and the solvent was evaporated. The crude product was chromatographed 
on silica gel with dichloromethane and ethyl acetate 1:1 as eluent. The fractions were 
collected and evaporated resulted in (8) (Figure 17) (661 mg, 66.12%).
31
 Melting point: 
99-100°C.
 1
H NMR (500MHz, CDCl3, ppm):  2.42 (s, 1H, OH), 3.76, 3.88, 3.90, 3.92 (s, 
3H, OCH3), 4.84 (s, 2H, CH2), 6.80 (s, 2H, ArH), 6.91 (s, 1H, ArH). IR (UATR cm
-1
): 
3530 (OH), and 1070 cm
-
1. Elemental Analysis for (C15H18O5): Calculated, C, 64.74; H, 
6.52%.Found, C, 64.70; H, 6.58%. 
2.9. 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthaquinone (C13H12O5) (9) 
Structure  
                                        
R = CH2OH 
Figure 18: Structure of compound (9a) and (9b) 
(9a) 
 
(9b) 
 
+ 
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Reaction 
 
 
Scheme 10: Preparation of compound (9a) and (9b) from (8) 
A solution of cerium ammonium nitrate (CAN) (2.5-3 mmol) (1.37-1.40 g) in 
water (5 mL) was added drop wise to a solution of compound (8) (0.292 g, 1mmol) in 
acetonitrile (10 mL) at room temperature for 30 min. When the addition of CAN started 
the solution turned from light brown colour to orange colour and then finally deep orange 
colour (Scheme 10). The reaction mixture was diluted with water, extracted with 
chloroform, washed with brine, finally dried over sodium sulfate, and concentrated 
(Figure 18). The residue was purified by chromatography on silica gel with 
dichloromethane and ethyl acetate 1:1 as eluent and recrystallized.
32   
Fraction a: 2-Hydroxymethyl-5,8-dimethoxy-1,4-naphthaquinone 
The second fraction from silica gel chromatography as dichloromethane and ethyl 
acetate 1:1 as eluent resulting in orange crystals (from ethanol). Melting point: 176-
177°C.
 1
H NMR (500 MHz, CDCl3, ppm):  2.10 (t, 1H,
3
J=2.70 Hz, OH), 3.99, 4.00 
(each, s, 6H, OCH3), 5.30 (dd, 2H, 
3
J= 5.50 Hz, CH2), 6.86 (t, 3J= 6.20 Hz, 1H, quinone 
ring H) and 7.77(s, 2H, benzene ring H). (IR (UATR cm
-1
): 3480, 3350, 1640(C=O), 
1585, 1565, 1075, 1045 cm
-1
. 
 
(9b) 
 
(9a) 
 
(8) 
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Fraction b: 2-Hydroxymethyl-1,4-dimethoxy-5,8-naphthaquinone  
The first fraction from silica gel chromatography as dichloromethane and ethyl 
acetate 1:1 as eluent resulting in orange semisolid.
30 
Melting point: 135-136 °C.
 1
H NMR 
(500MHz, CDCl3, ppm):  2.24 (t, 1H,
3
J= 3.20 Hz, OH), 3.99, 4.00 (each, s, 3H, OCH3), 
4.85 (d, 2H,
3
J=4.50 Hz CH2), 6.70 (s, 2H, quinone ring H) and 7.55 (s, 1H, benzene ring 
H). 
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CHAPTER THREE 
RESULTS AND DISCUSSIONS 
 
3.1. 1,5-dimethoxynaphthalene (C12H12O2)(1) 
 Compound (1) 1,5-dimethoxynaphthalene was prepared from the starting material 
1,5-dihydroxynaphthalene by direct substitution reaction. The hydrogen atoms on 1st and 
2nd position were removed and methyl group was directly substituted to oxygen atom 
resulting in methoxy group. Dimethyl sulfate and sodium hydroxide were added in a 
continuous mode for maintaining a moderately alkaline pH. This step was very useful for 
optimizing the quantity of methylating agent during scale up.
33 
Sodium dithionite was 
used as reducing agent in aqueous solution and also helped in eliminating residual oxide 
and improving overall color quantity. Compound (1) resulted in a very high yield and 
very rich yellow color by several washes with water and sodium hydroxide which helped 
in maintaining the pH. Finally the crude product was chromatographed on silica gel to 
yield a very pure product.
34 
The  
1
H NMR (500 MHz, CDCl3, ppm) revealed the hydrogens of the aromatic system as 
a doublet at  6.85 (s, 4H, ArH) having a J value of 6.2 Hz, triplet at 7.36 having a J value 
of 5.4 Hz, doublet at 7.83 having a J value of 8.5 Hz and for methoxy group as a singlet 
at 3.75 (s, 12H, OCH3) (Figure 19). 
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NMR Spectroscopy 
 
 
 
Figure 19: 
1
H NMR of 1,5-dimethoxynaphthalene (1) 
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3.2. 4,8-dibromo 1,5-dimethoxy naphthalene (C12H10O2Br2)(2) 
 
 
Scheme 11: Mechanism of N-bromosuccimide 
 Compound (2) 4,8-dibromo-1,5-dimethoxy naphthalene was prepared by using 
compound (1) as starting material. The bromination was carried out by using N-
bromosuccimide as brominating agent as it acted as free radical and addition of NBS was 
done drop by drop for about 30min (Scheme 11).
35
Initially the bromination was carried 
out with recrystallized NBS and the NBS was recrystallized from water. There was a 
main problem with monitoring the temperature for the addition of NBS. The temperature 
maintained during the addition was 10° C but the temperature played a very important 
role, the starting material turned into black immediately after the addition of NBS as the 
temperature was very high for the bromination. Then various test reactions were carried 
out for figuring out the temperature the reactions were carried out from -5° C to 5°C. But 
still there was a problem for the bromination; the starting material was yellow in color 
but as the temperature increased the color of the mixture turned black.  Finally the 
temperature was figured to be -10° C during the addition of NBS and the product was 
resulted in high yield. The temperature played a very important role as if there would be 
any change in the temperature the product would turn into black and also there were 
chances for the formation of mono substituted bromo compounds.
36
  
CH3CN 
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The 
1
H NMR (500 MHz, CDCl3, ppm) revealed the presence of brominated product as a 
singlet for methoxy protons at 4 and as a doublet for hydrogens of the aromatic system at 
6.82 having a J value of 5.5 Hz and 7.98 having a J value of 1 Hz (Figure 20). 
NMR Spectroscopy 
 
Figure 20: 
1
H NMR of 4,8-dibromo-1,5-dihydroxynaphthalene (2) 
3.3. 1,4,5,8-tetramethoxynaphthalene (C14H16O4)(3) 
 For the preparation of compound (3) the reaction involved is methoxylation as the 
bromine from the compound (2) needed to be removed and methoxy was added. The 
methoxylation was a type of substitution reaction and it generally exhibited second order 
33 
 
kinetics. The nucleophilic substitution reaction in this step takes place via four center 
mechanism involving interaction between the cuprous methoxide and aryl bromide.
37
 The 
copper iodide in the reaction was used as catalyst, DMF as solvent, three moles of 
sodium methoxide acted as base and out of three moles one mole was consumed by 
proton and the other two moles for the substitution reaction. Oxygen anion charge 
delocalized into the aromatic nucleus thereby deactivating the ring to further substitution 
reaction. Bromide was a better leaving group due to its larger atomic radius a concerted 
four center mechanism involving CH3OCu and C-Br could be envisaged. Under these 
conditions the simultaneous formation of the C-OCH3 bond and of NaBr was 
facilitated.
38 
 The 
1
H NMR (500MHz, CDCl3 , ppm) revealed that the presence of methoxy 
groups as a singlet at  6.84 (s, 4H, ArH) and for the methoxy groups as a singlet at 3.88 
(s,12H, OCH3)(Figure 21). 
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NMR Spectroscopy 
 
Figure 21: 
1
H NMR of 1,4,5,8-tetramethoxynaphthalene (3) 
3.4. 2-Formyl-1,4,5,8-tetramethoxynaphthalene(C14H16O4)(4) 
 Compound (4) 2-Formyl-1,4,5,8-tetramethoxynaphthalene was prepared by 
Vilsmeier- Haack reaction. The reaction takes place between substituted amide and 
phosphorus oxychloride and generates chloroiminium ion called vilsmeier reagent, which 
produces electrophilic iminium cation. The reaction proceeded by the attack of the 
35 
 
oxygen of the carbonyl group  of the amide to form the adduct which later reacts to 
produce the chloromethylene iminium salt. It was suggested that the initial adduct formed 
from POCl3 and DMF.
39
 The conventional Vilsmeier Haack reaction involves the 
reaction of the electron rich aromatic compounds or alkenes with the iminium salts 
obtained from formamides and acid chlorides. The initial step was an iminoalkylation 
which was essentially an electrophilic substitution where the iminium salt of the type 2 or 
3 acts as the electrophile. The reaction leads to the formation of an aldehyde on alkaline 
hydrolysis (Scheme 12).
40 
The 
1
H NMR (500 MHz, CDCl3, ppm) revealed the presence of aldehyde as a singlet at 
10.55 (s, 1H), as a singlet at 7.16 (s, 1H), doublet at 7.01 (d, 1 H) having a J value of 5.5 
Hz, as a doublet at 6.93 (d, 1H) having a J value of 9.5 Hz for aromatic hydrogens. For 
methoxy hydrogens as a singlet at 3.99 (s, 3H, OCH3), 3.98 (s, 3 H, OCH3), 3.91 (s, 3 H, 
OCH3)(Figure 23 and 24). 
 
 
36 
 
Scheme 12: Mechanism of Vilsmeier Haack reaction 
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NMR Spectroscopy 
 
 
Figure 22: 
1
H NMR of 2-Formyl-1,4,5,8-tetramethoxynaphthalene (4) with aromatic 
protons. 
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Figure 23: 
1
H NMR of 2-Formyl-1,4,5,8-tetramethoxynaphthalene (4) with methoxy 
protons. 
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3.5. 2-Formyl-1,4,5,8-tetramethoxynaphthaquinone(C13H10O5)(5) 
 The compound (5a) and (5b) were prepared by demethylating compound (4) with 
CAN and water as quinone received two heavy oxygen atoms in their carbonyls from the 
heavy water medium. There was formation of two kinds of intermediates one was 
electron donating and the other was when R was electron with drawing. The R substituted 
compounds would form a radical cation R that would help in its formation and 
stabilization. Water attacked the complex and the radical was formed for the subsequent 
oxidation of the para positional methoxyl by another ion affords and the final product 
(5a) was resulted (Scheme 13). On the other hand if R was an electron withdrawing 
group then the compound (5b) was resulted (Scheme 14).
41 
 The 
1
H NMR (500MHz, CDCl3 ,  ppm) revealed that the presence of methoxy 
groups as a singlet at 3.99, 4.01 (each s, 6H, OCH3), presence of hydrogens at quinone 
ring as a singlet at 6.85 (s, 2H, quinone ring), presence of aromatic hydrogens as a singlet 
at 7.75 (s, 2H, benzene ring), 10.49 (s, H)(Figure 24 and 25). 
 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
Scheme 13: Mechanism of Cerium ammonium nitrate on R groups 
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Scheme 14: Mechanism of Cerium ammonium nitrate on R groups 
 
 
 
42 
 
NMR Spectroscopy 
 
 
Figure 24: 
1
H NMR of 2-Formyl-1,4-dimethoxy 5,8-naphthaquinone (5a) 
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Figure 25: 
1
H NMR of 2-Formyl-5,8-dimethoxy 1,4-naphthaquinone (5b) 
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3.6. 2-(1-Hydroxyethyl)-1,4,5,8-tetramethoxynaphthalene(C16H20O5)(6) 
 The preparation of compound (6) from compound (4) was done with the help of 
grignard reagent methyl magnesium iodide. The carbon carbon bonds in aldehyde or 
ketone are formed due to the grignard reagent. 
31
 The magnesium halides in Grignard 
reagent attack the electrophilic carbon atom of a carbonyl group. The addition of the 
grignard reagent to the carbonyl typically proceeds through a six membered ring 
transition state.
31,41 
 1
H NMR (500MHz, CDCl3 ,  ppm) revealed the presence of methyl as a doublet at 
1.50 (d, 3H, CH3) having a J value of 4.5 Hz, a very broad singlet at  2.23 (broad, 1H, 
OH), presence of methoxy groups as a singlet at 3.76, 3.89 (each s, 3H, OCH3), 3.93 (s, 
6H, OCH3), a quadrat at 5.43 (q, 1H, CH), presence of aromatic hydrogens as a singlet at 
6.81 (s, 2H, ArH) and as a singlet at 7.00 (s, 1H, ArH)(Figure 26 and 27). 
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NMR Spectroscopy 
 
 
 
Figure 26: 
1
H NMR of 2-(1-Hydroxyethyl)-1,4,5,8-tetramethoxynaphthalene (6) from 1.5 
ppm - 2.4 ppm 
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Figure 27: 
1
H NMR of 2-(1-Hydroxyethyl)-1,4,5,8-tetramethoxynaphthalene (6) from 5.1 
ppm - 7.5 ppm 
 
 
 
 
 
 
 
47 
 
3.7. 2-(1-Hydroxyethyl)-1,4,5,8-tetramethoxynapthaquinone(C14H14O5)(7) 
NMR Spectroscopy of (7a) 
 The 
1
H NMR (500MHz, CDCl3,  ppm) revealed that the presence of methyl 
hydrogens at 1.48 (3H, CH3), a broad singlet at 2.70 (d, 1H, OH) having a J value of 2.5, 
a very strong peak at 3.96, 3.97 (each s, 3H, OCH3), a multiplet at 4.94 (m, 1H, CH) 
having a J value of 5.0, presence of aromatic hydrogens as a doublet at 6.78 (d, 1H, 
quinone ring) having a J value of 3.0 and as a singlet at 7.32 (s, 2H, benzene ring)(Figure 
28). 
 
 
Figure 28:
1
H NMR of 2-(1-Hydroxyethyl)-1,4-dimethoxy-5,8-napthaquinone (7a) 
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NMR Spectroscopy for (7b) 
 The 
1
H NMR (500MHz, CDCl3 , ppm) revealed the presence of methyl hydrogens 
as a doublet at 1.56 (d, 3H, CH3) having a J value of 3.2 , a very broad singlet at 2.2 
(broad, 1H, OH), for methoxy protons as a singlet at 3.83, 3.99 (each s, 3H, OCH3), a 
quadrat at 5.30 (q, 1H, CH) having a J value of 4.0, presence of aromatic hydrogens as a 
singlet at 6.76 (s, 2H, quinone ring H) and 7.55 (s, 1H, quinone ring H)(Figure 29). 
 
 
Figure 29: 
1
H NMR of 2-(1-Hydroxyethyl)-5,8-dimethoxy-1,4-napthaquinone (7b) 
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3.8. 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene(C15H18O5)(8) 
 Lithium aluminium hydride acted as a most nucleophilic reducing agent because 
hydride transfer to the carbonyl carbon occurs prior to the coordination to the carbonyl 
oxygen which was best used to reduce bonds like (C=O). It can also breakdown 
aldehydes, carboxylic acids and esters and ketones to primary and secondary alcohols 
respectively. The least stability and strength of Al-H bond in LiAlH4 reduces aldehyde 
into alcohol completely by the attack on carbonyl carbon with the nucleophilic hydride 
ion resulting in tetrahedral intermediate. The mechanism involves the transfer of a 
hydride onto the carbonyl carbon. Further the oxygen atom bonds to the aluminium 
hydride resulting in alkoxytrihydroaluminate ion. The resulted intermediate helps in the 
reduction of the next carbonyl molecule. In this way the compound (4) was reduced to 
compound (8). 
 The 
1
H NMR (500MHz, CDCl3,  ppm) revealed the presence of OH as a broad 
singlet at 2.42 (s, 1H, OH), presence of methoxy hydrogens as a singlet at 3.76, 3.88, 
3.90, 3.92 (each, s, 3H, OCH3), for methyl group as a singlet at 4.84 (s, 2H, CH2), for 
aromatic hydrogens as a singlet at 6.80 (s, 2H, ArH), 6.91 (s, 1H, ArH)(Figure 30, 31, 
32). 
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NMR Spectroscopy 
 
 
Figure 30: 
1
H NMR of 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene (8) 
51 
 
 
Figure 31:
1
H NMR of 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene (8) 
 
Figure 32: 
1
H NMR of 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthalene (8) 
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3.9. 2-Hydroxymethyl-1,4,5,8-tetramethoxynaphthaquinone(C13H12O5)(9) 
NMR Spectroscopy of (9a) 
The 
1
H NMR (500MHz, CDCl3,  ppm) revealed the presence of OH as a broad triplet at 
2.10 (t, 1H, OH) having a J value of 2.70, methoxy groups as a singlet at 3.99, 4.00 (each, 
s, 6H, OCH3), methyl group at 5.30 (dd, 2H, CH2) having a J value of 5.50, hydrogens at 
6.86 (t, 1H, quinone ring H) having a J value of 6.20 and 7.77(s, 2H, benzene ring 
H)(Figure 33). 
 
Figure 33:
 1
H NMR of 2-Hydroxymethyl-1,4 dimethoxy-5,8-naphthaquinone (9a) 
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NMR Spectroscopy of (9b) 
The 
1
H NMR (500MHz, CDCl3,  ppm) revealed the presence of OH group as a broad 
triplet at 2.24 (t, 1H, OH) having a J value of 3.20, methoxy groups at 3.99, 4.00 (each, s, 
3H, OCH3), methyl group at 4.85 (d, 2H, CH2) having a J value of 4.50, hydrogens at 
6.70 (s, 2H, quinone ring H) and 7.55 (s, 1H, benzene ring H)(Figure 34). 
 
Figure 34: 
1
H NMR of 2-Hydroxymethyl-5,8-dimethoxy-1,4 naphthaquinone (9b) 
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CHAPTER FOUR 
CONCLUSION 
 
In this research project we were able to synthesize three naphthaquinone 
derivatives as HER2 inhibitors with different chain lengths substituted at the 2
nd
 position 
of the naphthaquinone ring system. In the synthesis of precursor (2) the temperature and 
the purity of the starting material played a very important role. It is critical to remove the 
impurities by washing the product using acetonitrile and methanol. The proper 
temperature for this reaction was found to be -10C. All precursors used for the syntheses 
of compounds (5a), (5b), (7a), (7b), (9a), and (9b) (Table 2) were confirmed by 
1
H 
NMR and FTIR. The fractions were separated by column chromatography (Figure 35). 
The successful synthesis and separation of naphthaquinone derivatives were 
characterized and confirmed by 
1
H NMR, FTIR, melting points, and elemental analysis. 
                                        
 
Figure 35: Schematic of two fractions 
 
 
 
a b 
+ 
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Table 2: List of naphthaquinone analogues 
 
Compound  
 
R group 
5a and 5b CHO 
7a and 7b                        CH(OH)CH3 
 
9a and 9b CH2OH 
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CHAPTER5 
FUTURE WORK 
 
 
Molecular modeling will be performed to investigate the effect of our 
newly prepared compounds on the tyrosine kinase active site of HER2 including 
bonding interactions, surface properties, protein folding, and conformational 
changes of HER2 receptors. This information will be further used by modifying 
their structural characteristics and will guide the synthesis of the prospective 
inhibitors. 
Further the prepared inhibitors will be screened in selected breast cancer 
cell lines to study their cancer cell growth inhibition activities. Compounds that 
show significant cancer cell growth inhibition will be studied for their HER2 
inhibition activities through various immunohistochemical approaches. The 
synthesized compounds then can be evaluated to isolate the best compounds with 
inhibition activity and metabolic stability.   
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